Atlas Trials

Hellenic Society of Hematology

11 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Hellenic Society of Hematology

RecordFirmDate
A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY (NCT07019545)Hellenic Society of Hematology2025-06-20
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma (NCT05573802)Hellenic Society of Hematology2023-07-14
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory (NCT05581875)Hellenic Society of Hematology2022-10-20
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor (NCT05298683)Hellenic Society of Hematology2022-05-01
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible (NCT05280275)Hellenic Society of Hematology2022-04-13
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment (NCT05147493)Hellenic Society of Hematology2022-04-01
Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (NCT04808037)Hellenic Society of Hematology2021-02-22
Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma (NCT03475628)Hellenic Society of Hematology2018-02-21
Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment (NCT03450057)Hellenic Society of Hematology2018-02-15

Track Hellenic Society of Hematology automatically

Every clearance here is in the API, with alerts when new ones post.